BUYER READINESS
A working guide to what MEDDIC qualifies, where it goes quiet, and what to run underneath it.
If you've run the MEDDIC sales methodology for two quarters and your forecast still slips, this page is for you. The category reads a stalled deal as a selling failure, so it prescribes more selling: another demo, a tighter business case, a discount, a rep who tries harder. The deal still dies. The quarter still misses. The board still asks why the forecast was wrong. None of it is a selling failure, because the failure was never on your side of the table.
MEDDIC is doing its job. It qualifies whether a deal is worth your time. What it was never built to measure is whether the buyer on the other side can finish the decision you've qualified them for. Those are different questions, and only one of them explains a stalled pipeline.
The pillar lives at /buyer-readiness. Sibling head-to-heads: vs BANT, vs Challenger, vs SPIN.
What the MEDDIC Sales Methodology Measures, and Why It Earned Its Place
The six letters
Jack Napoli built MEDDIC at PTC in the late 1990s for enterprise software deals with long cycles and many stakeholders. The MEDDIC framework breaks qualification into six checks:
- Metrics. The quantifiable economic impact the buyer is chasing.
- Economic Buyer. The person with discretionary budget authority.
- Decision Criteria. The technical and business standards the buyer will judge against.
- Decision Process. The internal procurement and approval steps.
- Identify Pain. The specific business pain driving the purchase.
- Champion. The internal advocate who sells for you when you're not in the room.
Thirty years on, that list still holds up. It survived because it forces sellers to replace optimism with evidence. A rep who can fill in all six letters knows more about the deal than a rep working on feel.
What MEDDIC is actually a model of
Here is the part that matters for everything below. Every one of the six letters describes something the seller can observe, confirm, or influence. MEDDIC is a model of seller knowledge. It answers: do I know enough about this deal to forecast it?
That is a good question. It is not the same as: can this buyer decide?
The hidden assumption
MEDDIC treats the buyer's decision as a black box that does not need opening. Identify the right people, the right pains, the right criteria, and the qualification holds. The assumption is that a buying process, once observed, is stable and will run to completion.
Twenty-five years of decision research says otherwise, and so does the current data. Forrester finds that 86% of B2B purchases stall during the buying process. Those stalls happen inside the box MEDDIC doesn't open.
What DecisionScope Measures
DecisionScope scores the buyer's side across four dimensions. Each one is a distinct failure mode, and each has a matching resolution protocol. All four are defined in full on the buyer readiness pillar.
Problem Conviction
Does the buyer believe they have the problem you solve, strongly enough to act? Not “did they nod in discovery.” Conviction is the difference between agreeing a problem exists and believing the cost of leaving it alone is unacceptable. Agreement is cheap. The Urgency Protocol builds the second one, and it does the building before your first sales conversation, not during it.
Evaluation Clarity
Does the buyer know how to evaluate solutions like yours? Through Decision Criteria, MEDDIC comes closer to this dimension than to any other. It's also where the divergence runs deepest. MEDDIC asks whether you have captured the criteria. It doesn't ask whether the criteria are any good, or whether the buyer can apply them.
Start with the choice research, because it describes the mechanism your committee is running even though it wasn't run on one. How a buyer evaluates determines what they end up valuing: line the options up side by side and price wins, judge them one at a time and harder-to-measure things like fit and trust gain weight (Nowlis & Simonson, Journal of Marketing Research, 1997). And volume works against you, since information diversity and repetitiveness both degrade decision quality across 31 experiments (Hwang & Lin, Journal of Information Science, 1999). Neither study was run on a buying committee. Both describe how people weigh options under comparison, which is what a committee does. A buyer at this stage is drowning in information and short of a structure for ranking it.
The clinical literature then tells you how much a structure is worth, and it's the deepest evidence base anyone has on this question. Across 246 studies, structured decision aids reliably reduce decisional conflict, working hardest on the person who is genuinely unsure how to compare options (Garvelink et al., Medical Decision Making, 2019). One multicenter randomized trial cut “unsure” from 58% to 14% (Ladin et al., Annals of Internal Medicine, 2022), and a 1,117-participant cluster trial in 2025 found the effect held when the aid arrived before the engagement rather than inside it (Ozanne et al., BMJ, 2025). That last finding is the whole argument for running structure ahead of the evaluation.
One caveat I would rather raise than have you catch. That body of work studies patients, not buying committees, and nobody has run it on a thirteen-person enterprise evaluation. What transfers is the mechanism, a person facing an unfamiliar high-stakes choice with no structure for comparing options, and that mechanism is the same in a clinic and a conference room. The effect size does not transfer. Treat the direction as established here and the magnitude as an open question until somebody runs it on a buying committee.
The Framework Protocol supplies that structure before evaluation begins.
That evidence cuts at me too, and I'd rather say so than let you catch it. If information volume and repetitiveness degrade decision quality, then a badly built Framework Protocol is another twelve-slide deck with a nicer name on it. The finding doesn't exempt my own work because my work is the one being sold to you. What separates a decision aid from a brochure in that research is one thing only: structure the buyer can apply without me in the room. Not who wrote it. A Framework Protocol that only makes sense while I'm narrating it has failed by the same standard I just used on somebody else's capability deck.
Outcome Confidence
Does the buyer believe your solution delivers the outcome they need, in their environment? Metrics captures the number. Outcome Confidence measures belief in reaching it, and the two come apart more often than sellers expect.
A buyer can agree your product produces a 30% reduction in cycle time and still not believe it will happen at their company, with their data, their team, and their track record of stalled implementations. That gap isn't skepticism about your product. It's accurate memory of their own last few projects. Forrester's 2026 work finds 43% of buyers making defensive decisions more than 70% of the time, which is what buying looks like when the fear of being blamed for a failed rollout outweighs the upside of a successful one.
Reference customers don't usually fix this, because the reference is rarely close enough to the buyer's context to transfer. The Proof Protocol supplies implementation evidence and reference architecture matched to the buyer's actual environment rather than a logo slide.
Organizational Readiness
Can the buyer actually get this done inside their organization? Champion identifies the advocate. It doesn't measure whether the advocate can win. Forrester counts 13 stakeholders in the average B2B buying group, and Gartner finds 74% of buying teams in unhealthy conflict. The Alignment Protocol maps the group and equips the champion to sell internally.
The Weakest Link Principle
The four dimensions form a chain, and the deal moves at the speed of the weakest link. Three dimensions maxed and one incomplete isn't a strong deal with a minor gap. It's a dead deal, and that sentence is a working model rather than a measured finding. The four dimensions each rest on cited research. The chain claim on top of them, that the weakest one governs the whole, has no controlled trial behind it yet. I state it because it matches what the indecision literature predicts, not because someone has run the experiment. Every source behind these claims is listed in the full source table, with tier ratings and the eight findings that argue against the thesis.
Where They Overlap, and Where They Diverge
The comparison
| Axis | MEDDIC | DecisionScope |
|---|---|---|
| What it measures | Seller knowledge of the deal | Buyer capacity to decide |
| Whose side | Yours | Theirs |
| Scope | Deal qualification | Buyer readiness |
| Output | Qualified or not qualified | A score per dimension, plus the weakest link |
| When it runs | During the cycle, continuously | Before and during, diagnostically |
| Failure it catches | Wrong deal, wrong person, missing budget | Buyer cannot complete the decision |
| Failure it misses | Indecision inside a qualified deal | Whether the deal was worth qualifying |
| What you do with it | Pursue, deprioritize, or disqualify | Run the protocol matching the weakest dimension |
The verdict
MEDDIC says “this deal is worth pursuing.” DecisionScope says “this buyer is ready to decide.” Both sentences can be true. Both can be false. Both can be right about their own half and still miss the deal. When they disagree, the second one predicts your quarter. MEDDIC measures what you know. MEDDIC measures what you confirmed. MEDDIC measures what you can see from your own chair. What it cannot measure is the only thing that closes the quarter, and it was never built to. Holding that against it is a category error. The same mental model, framed from the seller's chair instead of the buyer's, is worked through in the buyer readiness gap.
Why the overlap is smaller than it looks
Decision Criteria and Decision Process look like they cover Evaluation Clarity. They don't. Capturing a buyer's stated criteria tells you what they said they'd judge on, which is not the same as what will survive contact with a committee.
The attribute-weighting research above is why. Criteria written into the CRM aren't a fixed object. They move with the format of the evaluation, so a list captured in a one-on-one discovery call describes a different decision than the one the committee actually runs side by side.
That's also why sending more material backfires. If diversity and repetitiveness degrade decision quality, then past a point every additional slide buys a worse decision, which should change how you think about the twelve-slide capability deck.
When the MEDDIC Sales Methodology Is Enough on Its Own
MEDDIC alone is sufficient more often than diagnostic vendors like to admit. Don't add a layer you don't need.
- Short cycles. Under thirty days, indecision has less room to compound.
- Observable decision processes. Where procurement is genuinely visible and stable, MEDDIC's Decision Process field carries real information.
- Mature categories. If your category is established, conviction work has already happened upstream and Problem Conviction arrives pre-built.
- Healthy win rates. Above 25% closed-won on qualified pipeline, your losses are more likely competitive than indecisive, and a diagnostic layer won't be where your gain comes from.
- Small buying groups. Two or three stakeholders means Organizational Readiness is close to observable, and Champion does most of the work.
If most of those describe your motion, run MEDDIC and run it well. Your energy will pay off somewhere else.
When You Need Readiness Diagnostics Underneath
- More than half your losses are “no decision.” This is the clearest signal. Dixon and McKenna found 40 to 60% of qualified B2B deals end in no decision, and 56% of those losses come from buyer indecision rather than preference for the status quo. Those are two different problems with two different fixes, and MEDDIC distinguishes neither.
- Deals pass qualification and stall anyway. A deal that clears all six letters and dies is the definition of a measurement gap. Ebsta and Pavilion's benchmark attributes 61% of B2B losses to buyer indecision.
- Your champion goes quiet after a strong demo. Champion was identified. Champion was engaged. Champion could not win the room. That's Organizational Readiness, and MEDDIC has no field for it. See why qualified deals die.
- Buyers ask for more information and then decide nothing. A meta-analysis of 31 experiments shows both information diversity and repetitiveness degrade decision quality (Hwang & Lin, Journal of Information Science, 1999). Gartner puts it more bluntly: information overload makes buyers 153% more likely to settle for a smaller purchase.
- Your pipeline grows and your close rate falls. That's volume arriving without conviction attached to it, a pattern covered in depth at demo pipeline close rate dropping.
Run the arithmetic on your own numbers rather than taking mine.
- Start with your qualified pipeline for the last four quarters.
- Multiply by the share that ended in no decision. Your CRM already knows this number and nobody looks at it.
- Multiply that by 61%, the share Ebsta and Pavilion attribute to indecision rather than to a competitor. What is left is the money that never had a rival bidding for it.
- Ask what recovering a quarter of that is worth against the cost of scoring four dimensions on deals you had already qualified anyway.
On $8M of qualified pipeline with 45% no-decision, the line reads $8M, then $3.6M, then $2.2M, then $550K. Substitute your three inputs and it runs itself. If it doesn't clear, the honest answer is that this isn't your bottleneck.
Three Ways MEDDIC Without Readiness Diagnostics Fails
Pattern one: the fully qualified corpse
Every letter filled in. Metrics agreed, Economic Buyer met, Criteria documented, Process mapped, Pain identified, Champion engaged. The deal sits in commit for two quarters and dies without a competitor ever entering. Nothing in MEDDIC fires a warning. Nothing in MEDDIC was wrong. Nothing in MEDDIC was ever pointed at the buyer. The buyer just couldn't finish.
Here is the shape it takes, drawn from a case I keep on file. It's an anonymized composite assembled from sales-community accounts, not a client of mine, and I'd rather tell you that than let you assume otherwise. An enthusiastic director ran point through three strong calls. Then he stopped replying. Weeks of silence, and when he resurfaced the deal was already dead: he had carried it into a committee the seller never met, and he couldn't answer the room's questions. Every MEDDIC letter had been green the whole time. Champion was the letter that was filled in, and Champion is exactly the letter that measured the wrong thing.
Three good calls measured one man's conviction.
Nobody measured whether the room he walked into alone had ever heard of the vendor.
This is the pattern the MEDDIC limitations analysis takes apart in detail.
Pattern two: criteria that were never the buyer's
Decision Criteria gets filled from what the champion says the committee will want. The champion is guessing. When the committee convenes, the real criteria surface, and they aren't the documented ones. Research on B2B buying shows digital channels dominate the pre-purchase phase where buyers self-direct, with personal selling effective only after buyers surface needs themselves (Andersson et al., 2024). By the time your rep documents criteria, much of the real evaluation has already happened without you.
Pattern three: pressure applied to the wrong failure
The deal stalls, so the team leans in. More follow-up, more urgency, a discount. Dixon and McKenna found that 73% of sellers default to the status quo playbook when deals stall, degrading win rates by 84%. Pressure works on a buyer who prefers the status quo. It backfires on a buyer who is afraid of making a mistake. MEDDIC can't tell you which one you're looking at, so the rep guesses. Most guess wrong. The economics of that conversation are worked through in the cost of inaction.
How to Run Both Together
- Qualify with MEDDIC first. Nothing changes here. If the deal isn't worth pursuing, no diagnostic saves it.
- Score the four dimensions on qualified deals only. Diagnosis is for deals that already passed, because running the instrument across unqualified pipeline just wastes it.
- Find the weakest link, and only the weakest. A chain that already moves at the speed of its slowest point gains nothing from strengthening a link that was never the constraint.
- Run the protocol that matches. Run one, not four. In plain terms, rather than as four capitalized nouns:
- Weak Problem Conviction gets the Urgency Protocol, which builds the case for change before your first sales conversation instead of during it.
- Weak Evaluation Clarity gets the Framework Protocol, which hands the buyer a decision structure they can apply without you in the room.
- Weak Outcome Confidence gets the Proof Protocol, which supplies implementation evidence matched to their environment rather than a logo slide.
- Weak Organizational Readiness gets the Alignment Protocol, which maps the buying group and equips the champion for the room he walks into alone.
- Re-score before you forecast. If a dimension moved, your forecast moved with it. If it didn't move after a protocol ran, you're looking at a deal to deprioritize, not a protocol to repeat.
For how the rest of this category stacks up, see the buyer indecision solutions comparison.
Start With Your Own Pipeline
Go back to the board asking why the forecast was wrong. Between 40 and 60% of qualified B2B deals end in no decision, so the odds are the forecast wasn't wrong about the deal at all. It was wrong about the buyer, and it was wrong because nothing in the qualification was measuring them.
MEDDIC isn't the reason. Dropping it isn't the fix. The only question worth your time is which of the four dimensions is carrying your weakest link right now.
You didn't lose those deals. Nobody ever decided.
Take the free Buyer Readiness Check, which takes four minutes and sits behind no gate.
FAQ
Does DecisionScope replace the MEDDIC sales methodology?
No. DecisionScope sits beneath qualification as a diagnostic layer, not in place of it. MEDDIC qualifies the deal; DecisionScope diagnoses the buyer. Drop MEDDIC to adopt a diagnostic and you lose the qualification discipline you already had without gaining anything the diagnostic was built to give you.
What is the difference between MEDDIC and MEDDPICC?
MEDDPICC adds Paper Process and Competition to the original six. Both additions are seller-side observations, which means MEDDPICC is a more complete map of the same territory rather than a map of new territory. It closes real gaps: Paper Process catches procurement drag that Decision Process often misses, and Competition forces a rep to name who else is in the room. Neither one opens the black box.
Is MEDDIC a sales methodology or a qualification framework?
A qualification framework, and the distinction matters more than it sounds. A methodology tells a seller how to sell. MEDDIC only tells a seller what to know. That is why it pairs cleanly with almost anything, including BANT and SPIN, and why the critique that it is a CRM exercise rather than a methodology is half right. It was never trying to be a methodology.
How does Organizational Readiness differ from the Champion letter in MEDDIC?
Champion asks whether an advocate exists. Organizational Readiness asks whether that advocate can win, given the buying group, the internal politics, and the approval path. With 13 stakeholders in the average B2B buying group, those are very different questions.
Will MEDDIC alone work for smaller deal sizes?
Often, yes. Shorter cycles and smaller buying groups mean less room for indecision to compound. The threshold is not deal size but loss composition: when more than half your losses end in no decision rather than a competitor, the diagnostic layer starts paying for itself regardless of deal size.
Where can I check the research behind this?
Every claim on this page is sourced in the full source table, which lists 135 sources with tier ratings, peer-review status, and the eight findings that disconfirm parts of the thesis. The disconfirming set is included deliberately.
How long does a buyer readiness assessment take?
The free readiness check takes about four minutes and is perception-based. The full diagnosis scores a real slice of your pipeline from your own CRM.